<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417780</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-201</org_study_id>
    <nct_id>NCT01417780</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients</brief_title>
  <official_title>Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atox Bio Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atox Bio Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and pharmacokinetics profile of different doses of AB103&#xD;
      administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled&#xD;
      for an urgent surgical intervention as part of their standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to evaluate the safety and pharmacokinetics profile of different doses of AB103&#xD;
      administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled&#xD;
      for an urgent surgical intervention as part of their standard of care. The primary study&#xD;
      hypothesis is that AB-103 can be administered safely to the patients presenting with&#xD;
      Necrotizing Soft Tissue Infections.&#xD;
&#xD;
      Secondary endpoints are efficacy by exploratory descriptive analyses of specific efficacy&#xD;
      endpoints from three outcome domains to demonstrate treatment benefit of AB103 in comparison&#xD;
      to placebo in patients with Necrotizing Soft Tissue Infections. The efficacy domains are:&#xD;
&#xD;
        1. Clinical status domain&#xD;
&#xD;
        2. Pharmacoeconomics domain&#xD;
&#xD;
        3. Systemic and local inflammatory biomarker domain&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period</measure>
    <time_frame>7 days</time_frame>
    <description>An AE is any untoward medical occurrence in a subject administered study drug and that does not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>A serious adverse event (SAE) is an AE occurring during any study phase and at any dose of the study drug (AB103 or placebo) that fulfills one or more of the following criteria:&#xD;
Results in death&#xD;
Is life-threatening (i.e., the subject was, in the opinion of the Investigator, at immediate risk of death from the event as it occurred)&#xD;
Requires or prolongs hospitalization&#xD;
Results in persistent or significant disability or incapacity (i.e., the event causes a substantial disruption of a person's ability to conduct normal life functions)&#xD;
Is a congenital anomaly or birth defect, or&#xD;
Is an important and significant medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening ALT results, Day 7 ALT results, and change in ALT from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening AST results, Day 7 AST results, and change in AST from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alkaline Phosphatase (ALP)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening ALP results, Day 7 ALP results, and change in ALP from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Bilirubin (Tbili)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening Tbili results, Day 7 Tbili results, and change in Tbili from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine (sCr)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening sCr results, Day 7 sCr results, and change in sCr from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin (Alb)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening Alb results, Day 7 Alb results, and change in Alb from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin (Hgb)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening Hgb results, Day 7 Hgb results, and change in Hgb from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total White Blood Cell (WBC) Count</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening WBC results, Day 7 WBC results, and change in WBC from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet (PLT) Count</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening PLT results, Day 7 PLT results, and change in PLT from screening to Day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Normalized Ratio (INR)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening INR results, Day 7 INR results, and change in INR from screening to Day 7. In general, the higher the INR value, the longer it takes for blood to form a clot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QT Interval With Fridericia's Correction (QTcF)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>Pre-dose QTcF, post-dose QTcF, change in QTcF from pre-dose to post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Categorical Change in QTcF</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>Number and percentage of patients with a change in QTcF of &gt; 30 msec; number and percentage of patients with a change in QTcF of &gt; 60 msec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero to infinity following a single dose of study drug, obtained by noncompartmental methods. It is an integrated measure of study drug plasma exposure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
    <description>Maximum plasma concentration (observed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Plasma Half-life (T1/2)</measure>
    <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
    <description>Apparent terminal plasma half-life (T1/2) is the amount of time for plasma concentrations to decline by 50%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
    <description>Clearance (CL) is the volume of plasma completely cleared of drug per unit of time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution Under Steady State Conditions (Vss)</measure>
    <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
    <description>Apparent volume of distribution under steady state conditions (Vss) based on drug concentration in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>Screening and Day 7</time_frame>
    <description>Screening CRP results, Day 7 CRP results, and change in CRP from screening to Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>14 days</time_frame>
    <description>Day 14 SOFA score is the sum of individual SOFA score components at Day 14. Results include last observation carried forward (LOCF) imputation for missing values.&#xD;
SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 Sequential Organ Failure Assessment (SOFA) Score Less Than or Equal to 1</measure>
    <time_frame>14 days</time_frame>
    <description>Number and percentage of patients with Day 14 Sequential Organ Failure Assessment (SOFA) score less than or equal to 1. SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay (LOS)</measure>
    <time_frame>28 days</time_frame>
    <description>The duration of hospital stay over the 28-day study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit-free Days (ICU-free Days)</measure>
    <time_frame>28 days</time_frame>
    <description>The number of intensive care unit-free days (ICU-free days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>28 days</time_frame>
    <description>The number of ventilator-free days (days without ventilator use)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Necrotizing Soft Tissue Infections</condition>
  <arm_group>
    <arm_group_label>AB103 0.25 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AB103 0.5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (0.9% sodium chloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB103</intervention_name>
    <description>AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion</description>
    <arm_group_label>AB103 0.25 mg/kg</arm_group_label>
    <arm_group_label>AB103 0.5 mg/kg</arm_group_label>
    <other_name>p2TA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Clinical diagnosis of NSTI due to bacterial infection (Necrotizing Fasciitis, Group A&#xD;
             streptococcal infection or non group A streptococcal infection, Fournier's gangrene,&#xD;
             Bacterial synergistic gangrene, Synergistic Necrotizing Cellulitis, Clostridial gas&#xD;
             gangrene/ myonecrosis) that may be supported by specific signs and symptoms, e.g.&#xD;
             tense edema outside area of compromised skin, pain disproportionate to appearance,&#xD;
             skin discoloration, ecchymosis, blisters/bullae, necrosis, tense edema, crepitus&#xD;
             and/or subcutaneous gas AND a decision for urgent surgical exploration and&#xD;
             debridement;&#xD;
&#xD;
          -  Patient who did not receive the study drug prior to the surgery need to have a&#xD;
             definite diagnosis of NSTI confirmed surgically (e.g. presence of necrotic tissue,&#xD;
             thrombosed vessels in the subcutaneous tissue, lack of bleeding and &quot;dishwater&quot;&#xD;
             (cloudy, thin, gray) fluid) in order to get the drug during or after operation;&#xD;
&#xD;
          -  IV drug administration within 6 hours from the clinical diagnosis and from the&#xD;
             documented decision to have an urgent surgical exploration and debridement;&#xD;
&#xD;
          -  Signed and dated ICF as defined by the IRB and, if applicable, California Bill of&#xD;
             Rights. By signing the ICF, the patient agrees to release any medical records pursuant&#xD;
             to current Health Insurance Portability and Accountability Act (HIPAA) Guidelines. If&#xD;
             patient is unable to comprehend or sign the ICF, patient's legally acceptable&#xD;
             representative may sign the ICF;&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Age &lt; 18 years;&#xD;
&#xD;
          -  Weight &gt; 150 Kg / 330 pounds;&#xD;
&#xD;
          -  Pregnant or lactating women; Female of childbearing potential, the patient must have a&#xD;
             negative beta subunit hCG pregnancy test immediately prior to study entry (performed&#xD;
             by urine or blood test, whichever is faster);&#xD;
&#xD;
          -  Patient who has been operated at least once for the current NSTI infection and had a&#xD;
             curative deep tissue debridement (diagnostic surgery is allowed to enter into the&#xD;
             study);&#xD;
&#xD;
          -  Known HIV infection with CD4 count &lt; 200 cells/mm3 or &lt; 14% of all lymphocytes;&#xD;
&#xD;
          -  Diabetic patients with below ankle infection;&#xD;
&#xD;
          -  Patients with overt peripheral vascular disease in the involved area - condition&#xD;
             associated with ischemic ulcers and /or symptoms of inadequate vascular supply (e.g.&#xD;
             intermittent claudication) where limb amputation is considered likely within 7 days;&#xD;
&#xD;
          -  Current status of: a. Mean arterial pressure &lt; 50 mmHg and/or systolic blood pressure&#xD;
             &lt; 70 mmHg despite treatment with vasopressors and/or IV fluids or b. a patient with&#xD;
             respiratory failure such that an SaO2 of 80% cannot be achieved or c. a patient with&#xD;
             refractory coagulopathy (INR &gt; 3) or d. thrombocytopenia (platelet count &lt; 20,000)&#xD;
             that does not partially correct with administration of appropriate factors, or e.&#xD;
             likely severe neurological impairment secondary to cardiac arrest.&#xD;
&#xD;
          -  Patients with cardiac arrest requiring cardiopulmonary resuscitation within the past&#xD;
             30 days;&#xD;
&#xD;
          -  Patient is not expected to survive 30 days because of underlying medical condition,&#xD;
             such as poorly controlled neoplasm (e.g. Stage III or IV cancer);&#xD;
&#xD;
          -  Any concurrent medical condition, which in the opinion of the investigator, may&#xD;
             compromise their safety or the objectives of the study or the patient will not benefit&#xD;
             from treatment, (e.g. end stage organ disease {CHF {NYHA class III-IV}, COPD {stage&#xD;
             III-IV}, Liver dysfunction {Childs-Pugh class C}, Renal dysfunction {Dialysis}),&#xD;
             immunosuppression, receiving or about to receive chemotherapy or known severe&#xD;
             neutropenia &lt; 1,000 cells/mm3;&#xD;
&#xD;
          -  Patients with Necrotizing Soft Tissue Infection post intra-abdominal operation;&#xD;
&#xD;
          -  Patient with burn wounds;&#xD;
&#xD;
          -  Patient or patient's family are not committed to aggressive management of the&#xD;
             patient's condition, or the combination of necrotizing skin infection and underlying&#xD;
             illness makes it unlikely that life support will be maintained;&#xD;
&#xD;
          -  Previous enrolment in an previous clinical trial involving investigational drug or a&#xD;
             medical device within 30 days before provision of written informed consent for the&#xD;
             study or within five half lives of the investigational drug, whichever is longer;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Southern California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldawer LL, Demetriades D, Talving P, Schreiber M, Ham B, Cohen M, Opal S, Segalovich I, Maislin G, Kaempfer R, Shirvan A. A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial. JAMA Surg. 2014 Jun;149(6):528-36. doi: 10.1001/jamasurg.2013.4841.</citation>
    <PMID>24740134</PMID>
  </results_reference>
  <results_reference>
    <citation>Bulger EM, Maislin G, Dankner W, May A, Edgar R, Shirvan A. Critical Care Medicine, January 2018,46(1):327. Abstract 682: Early Plasma Cytokine Levels Correlate With Outcome in Necrotizing Soft Tissue Infections. https://journals.lww.com/ccmjournal/Citation/2018/01001/682</citation>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>July 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2021</results_first_posted>
  <disposition_first_submitted>January 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted by qualified investigators under the sponsorship of Atox Bio Ltd. at 7 trauma centers, of which 6 enrolled patients from December 2011 through August 2012.</recruitment_details>
      <pre_assignment_details>Of 43 randomized patients who received AB103 or placebo (intent-to-treat [ITT] population; safety analyses), 3 patients were excluded to form the modified intent-to-treat (mITT) population before unblinding due to protocol violations. Therefore, a total of 40 patients were included in the mITT efficacy analyses. With respect to any variable, the number of patients analyzed is the number of patients with non-missing data within the respective population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AB103 0.25 mg/kg</title>
          <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="P2">
          <title>AB103 0.5 mg/kg</title>
          <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data are from the modified intent-to-treat (mITT) population. The mITT population consisted of all randomized patients who received the proper study drug (AB103 or placebo) and dose, had a definitive surgical diagnosis of NSTI, and did not have a CD4 count &lt;200 cells/mm3.</population>
      <group_list>
        <group group_id="B1">
          <title>AB103 0.25 mg/kg</title>
          <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="B2">
          <title>AB103 0.5 mg/kg</title>
          <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="13.6"/>
                    <measurement group_id="B2" value="50.1" spread="15.2"/>
                    <measurement group_id="B3" value="52.5" spread="20.4"/>
                    <measurement group_id="B4" value="50.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NSTI Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fournier Gangrene</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other NSTI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" spread="6.5"/>
                    <measurement group_id="B2" value="31.7" spread="9.7"/>
                    <measurement group_id="B3" value="29.9" spread="9.3"/>
                    <measurement group_id="B4" value="31.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Physiology And Chronic Health Evaluation II (APACHE II) Score</title>
          <description>APACHE II is a severity of illness classification system. It is determined within 24 hours of admission of a patient to an intensive care unit (ICU): an integer score from 0 to 71 is computed based on several measurements (physiologic variables, age, chronic health status).&#xD;
Higher scores correspond to more severe disease and a greater risk of death.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="5.0"/>
                    <measurement group_id="B2" value="8.3" spread="4.5"/>
                    <measurement group_id="B3" value="9.6" spread="4.7"/>
                    <measurement group_id="B4" value="8.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.87" spread="2.70"/>
                    <measurement group_id="B2" value="3.47" spread="2.53"/>
                    <measurement group_id="B3" value="3.10" spread="1.97"/>
                    <measurement group_id="B4" value="3.15" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Organ Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period</title>
        <description>An AE is any untoward medical occurrence in a subject administered study drug and that does not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug.</description>
        <time_frame>7 days</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period</title>
          <description>An AE is any untoward medical occurrence in a subject administered study drug and that does not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug.</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With One or More Serious Adverse Events (SAEs)</title>
        <description>A serious adverse event (SAE) is an AE occurring during any study phase and at any dose of the study drug (AB103 or placebo) that fulfills one or more of the following criteria:&#xD;
Results in death&#xD;
Is life-threatening (i.e., the subject was, in the opinion of the Investigator, at immediate risk of death from the event as it occurred)&#xD;
Requires or prolongs hospitalization&#xD;
Results in persistent or significant disability or incapacity (i.e., the event causes a substantial disruption of a person's ability to conduct normal life functions)&#xD;
Is a congenital anomaly or birth defect, or&#xD;
Is an important and significant medical event.</description>
        <time_frame>28 days</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With One or More Serious Adverse Events (SAEs)</title>
          <description>A serious adverse event (SAE) is an AE occurring during any study phase and at any dose of the study drug (AB103 or placebo) that fulfills one or more of the following criteria:&#xD;
Results in death&#xD;
Is life-threatening (i.e., the subject was, in the opinion of the Investigator, at immediate risk of death from the event as it occurred)&#xD;
Requires or prolongs hospitalization&#xD;
Results in persistent or significant disability or incapacity (i.e., the event causes a substantial disruption of a person's ability to conduct normal life functions)&#xD;
Is a congenital anomaly or birth defect, or&#xD;
Is an important and significant medical event.</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alanine Aminotransferase (ALT)</title>
        <description>Screening ALT results, Day 7 ALT results, and change in ALT from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <description>Screening ALT results, Day 7 ALT results, and change in ALT from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="99.8"/>
                    <measurement group_id="O2" value="28.1" spread="17.3"/>
                    <measurement group_id="O3" value="46.8" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="18.8"/>
                    <measurement group_id="O2" value="27.3" spread="26.3"/>
                    <measurement group_id="O3" value="26.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="95.1"/>
                    <measurement group_id="O2" value="-0.8" spread="31.2"/>
                    <measurement group_id="O3" value="-19.8" spread="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>Screening AST results, Day 7 AST results, and change in AST from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <description>Screening AST results, Day 7 AST results, and change in AST from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="30.6"/>
                    <measurement group_id="O2" value="37.4" spread="28.3"/>
                    <measurement group_id="O3" value="32.0" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="17.1"/>
                    <measurement group_id="O2" value="24.3" spread="10.1"/>
                    <measurement group_id="O3" value="27.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="30.7"/>
                    <measurement group_id="O2" value="-9.3" spread="21.7"/>
                    <measurement group_id="O3" value="0.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alkaline Phosphatase (ALP)</title>
        <description>Screening ALP results, Day 7 ALP results, and change in ALP from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase (ALP)</title>
          <description>Screening ALP results, Day 7 ALP results, and change in ALP from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="53.5"/>
                    <measurement group_id="O2" value="104.3" spread="47.7"/>
                    <measurement group_id="O3" value="108.3" spread="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" spread="45.2"/>
                    <measurement group_id="O2" value="84.8" spread="33.9"/>
                    <measurement group_id="O3" value="100.6" spread="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="40.1"/>
                    <measurement group_id="O2" value="-10.6" spread="62.3"/>
                    <measurement group_id="O3" value="-11.4" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Bilirubin (Tbili)</title>
        <description>Screening Tbili results, Day 7 Tbili results, and change in Tbili from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin (Tbili)</title>
          <description>Screening Tbili results, Day 7 Tbili results, and change in Tbili from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="0.8"/>
                    <measurement group_id="O3" value="1.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                    <measurement group_id="O3" value="1.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.6"/>
                    <measurement group_id="O2" value="-0.5" spread="0.5"/>
                    <measurement group_id="O3" value="-0.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Creatinine (sCr)</title>
        <description>Screening sCr results, Day 7 sCr results, and change in sCr from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine (sCr)</title>
          <description>Screening sCr results, Day 7 sCr results, and change in sCr from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.9"/>
                    <measurement group_id="O2" value="1.3" spread="1.7"/>
                    <measurement group_id="O3" value="1.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="2.0"/>
                    <measurement group_id="O3" value="-0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Albumin (Alb)</title>
        <description>Screening Alb results, Day 7 Alb results, and change in Alb from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin (Alb)</title>
          <description>Screening Alb results, Day 7 Alb results, and change in Alb from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.9"/>
                    <measurement group_id="O2" value="2.1" spread="0.5"/>
                    <measurement group_id="O3" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.9"/>
                    <measurement group_id="O2" value="1.7" spread="0.4"/>
                    <measurement group_id="O3" value="2.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.4"/>
                    <measurement group_id="O2" value="-0.3" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin (Hgb)</title>
        <description>Screening Hgb results, Day 7 Hgb results, and change in Hgb from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin (Hgb)</title>
          <description>Screening Hgb results, Day 7 Hgb results, and change in Hgb from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="2.2"/>
                    <measurement group_id="O2" value="11.0" spread="1.5"/>
                    <measurement group_id="O3" value="10.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="2.1"/>
                    <measurement group_id="O2" value="8.9" spread="1.1"/>
                    <measurement group_id="O3" value="9.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.1"/>
                    <measurement group_id="O2" value="-2.5" spread="1.5"/>
                    <measurement group_id="O3" value="-1.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total White Blood Cell (WBC) Count</title>
        <description>Screening WBC results, Day 7 WBC results, and change in WBC from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total White Blood Cell (WBC) Count</title>
          <description>Screening WBC results, Day 7 WBC results, and change in WBC from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>thousand cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="10.0"/>
                    <measurement group_id="O2" value="14.7" spread="8.8"/>
                    <measurement group_id="O3" value="21.7" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="6.7"/>
                    <measurement group_id="O2" value="12.5" spread="5.1"/>
                    <measurement group_id="O3" value="12.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="9.3"/>
                    <measurement group_id="O2" value="-3.0" spread="10.9"/>
                    <measurement group_id="O3" value="-11.2" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Platelet (PLT) Count</title>
        <description>Screening PLT results, Day 7 PLT results, and change in PLT from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet (PLT) Count</title>
          <description>Screening PLT results, Day 7 PLT results, and change in PLT from screening to Day 7</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug (N=43). The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>thousand cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.2" spread="182.2"/>
                    <measurement group_id="O2" value="215.1" spread="82.0"/>
                    <measurement group_id="O3" value="255.3" spread="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.5" spread="168.8"/>
                    <measurement group_id="O2" value="341.8" spread="140.6"/>
                    <measurement group_id="O3" value="318.3" spread="148.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="237.1"/>
                    <measurement group_id="O2" value="125.1" spread="144.6"/>
                    <measurement group_id="O3" value="49.9" spread="160.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Normalized Ratio (INR)</title>
        <description>Screening INR results, Day 7 INR results, and change in INR from screening to Day 7. In general, the higher the INR value, the longer it takes for blood to form a clot.</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The safety analysis population consisted of all randomized patients who received study drug. One of the 0.25 mg/kg patients did not have a Screening INR result. Participant numbers in some rows differ from the overall number analyzed due to missing data as conveyed in the number of participants in each treatment group within a row.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>International Normalized Ratio (INR)</title>
          <description>Screening INR results, Day 7 INR results, and change in INR from screening to Day 7. In general, the higher the INR value, the longer it takes for blood to form a clot.</description>
          <population>The safety analysis population consisted of all randomized patients who received study drug. One of the 0.25 mg/kg patients did not have a Screening INR result. Participant numbers in some rows differ from the overall number analyzed due to missing data as conveyed in the number of participants in each treatment group within a row.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.22"/>
                    <measurement group_id="O2" value="1.43" spread="0.33"/>
                    <measurement group_id="O3" value="1.41" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                    <measurement group_id="O3" value="1.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.2"/>
                    <measurement group_id="O2" value="-0.2" spread="0.3"/>
                    <measurement group_id="O3" value="-0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>QT Interval With Fridericia's Correction (QTcF)</title>
        <description>Pre-dose QTcF, post-dose QTcF, change in QTcF from pre-dose to post-dose</description>
        <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
        <population>Safety population: all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data as noted in results.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>QT Interval With Fridericia's Correction (QTcF)</title>
          <description>Pre-dose QTcF, post-dose QTcF, change in QTcF from pre-dose to post-dose</description>
          <population>Safety population: all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data as noted in results.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose QTcF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.1" spread="39.3"/>
                    <measurement group_id="O2" value="401.8" spread="16.8"/>
                    <measurement group_id="O3" value="405.1" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dose QTcF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.2" spread="23.1"/>
                    <measurement group_id="O2" value="403.1" spread="39.3"/>
                    <measurement group_id="O3" value="407.4" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTcF from pre-dose to post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="37.2"/>
                    <measurement group_id="O2" value="1.3" spread="36.1"/>
                    <measurement group_id="O3" value="8.9" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Categorical Change in QTcF</title>
        <description>Number and percentage of patients with a change in QTcF of &gt; 30 msec; number and percentage of patients with a change in QTcF of &gt; 60 msec</description>
        <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
        <population>Safety population: all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data as noted in results.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Change in QTcF</title>
          <description>Number and percentage of patients with a change in QTcF of &gt; 30 msec; number and percentage of patients with a change in QTcF of &gt; 60 msec</description>
          <population>Safety population: all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data as noted in results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with a change in QTcF of &gt; 30 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with a change in QTcF of &gt; 60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
        <description>Area under the plasma concentration versus time curve (AUC) from time zero to infinity following a single dose of study drug, obtained by noncompartmental methods. It is an integrated measure of study drug plasma exposure.</description>
        <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
        <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC)</title>
          <description>Area under the plasma concentration versus time curve (AUC) from time zero to infinity following a single dose of study drug, obtained by noncompartmental methods. It is an integrated measure of study drug plasma exposure.</description>
          <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
          <units>ng*min/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8497" lower_limit="2836" upper_limit="14269"/>
                    <measurement group_id="O2" value="16921" lower_limit="4843" upper_limit="28952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>Maximum plasma concentration (observed)</description>
        <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
        <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>Maximum plasma concentration (observed)</description>
          <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="899" lower_limit="98" upper_limit="2664"/>
                    <measurement group_id="O2" value="1484" lower_limit="661" upper_limit="3418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Plasma Half-life (T1/2)</title>
        <description>Apparent terminal plasma half-life (T1/2) is the amount of time for plasma concentrations to decline by 50%.</description>
        <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
        <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Plasma Half-life (T1/2)</title>
          <description>Apparent terminal plasma half-life (T1/2) is the amount of time for plasma concentrations to decline by 50%.</description>
          <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="1.28" upper_limit="18.99"/>
                    <measurement group_id="O2" value="4.89" lower_limit="1.53" upper_limit="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance (CL)</title>
        <description>Clearance (CL) is the volume of plasma completely cleared of drug per unit of time.</description>
        <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
        <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Clearance (CL) is the volume of plasma completely cleared of drug per unit of time.</description>
          <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.42" lower_limit="17.52" upper_limit="88.14"/>
                    <measurement group_id="O2" value="29.55" lower_limit="17.27" upper_limit="103.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution Under Steady State Conditions (Vss)</title>
        <description>Apparent volume of distribution under steady state conditions (Vss) based on drug concentration in plasma</description>
        <time_frame>Prior to infusion, at mid infusion time, end of infusion, and at 2, 5, 10, 20, 30, 60 min and 120 minutes after completion of the IV infusion of study drug.</time_frame>
        <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution Under Steady State Conditions (Vss)</title>
          <description>Apparent volume of distribution under steady state conditions (Vss) based on drug concentration in plasma</description>
          <population>The pharmacokinetic (PK) analysis population consisted of all intent-to-treat (ITT) patients who received study drug and had a baseline and at least one post-baseline specified plasma sample obtained for quantitative analysis. The number of subjects analyzed reflects the number of subjects for which the parameter could be determined.</population>
          <units>mL/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="53" upper_limit="157"/>
                    <measurement group_id="O2" value="135" lower_limit="36" upper_limit="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (CRP)</title>
        <description>Screening CRP results, Day 7 CRP results, and change in CRP from screening to Day 7</description>
        <time_frame>Screening and Day 7</time_frame>
        <population>The population is all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP)</title>
          <description>Screening CRP results, Day 7 CRP results, and change in CRP from screening to Day 7</description>
          <population>The population is all randomized patients who received study drug. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="12.3"/>
                    <measurement group_id="O2" value="27.5" spread="6.2"/>
                    <measurement group_id="O3" value="20.6" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="10.0"/>
                    <measurement group_id="O2" value="7.5" spread="4.4"/>
                    <measurement group_id="O3" value="4.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Screening to Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="14.6"/>
                    <measurement group_id="O2" value="-22.7" spread="5.9"/>
                    <measurement group_id="O3" value="-20.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 14 Sequential Organ Failure Assessment (SOFA) Score</title>
        <description>Day 14 SOFA score is the sum of individual SOFA score components at Day 14. Results include last observation carried forward (LOCF) imputation for missing values.&#xD;
SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>14 days</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Day 14 Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>Day 14 SOFA score is the sum of individual SOFA score components at Day 14. Results include last observation carried forward (LOCF) imputation for missing values.&#xD;
SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.00"/>
                    <measurement group_id="O2" value="0.71" spread="0.83"/>
                    <measurement group_id="O3" value="2.70" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 14 Sequential Organ Failure Assessment (SOFA) Score Less Than or Equal to 1</title>
        <description>Number and percentage of patients with Day 14 Sequential Organ Failure Assessment (SOFA) score less than or equal to 1. SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
        <time_frame>14 days</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Day 14 Sequential Organ Failure Assessment (SOFA) Score Less Than or Equal to 1</title>
          <description>Number and percentage of patients with Day 14 Sequential Organ Failure Assessment (SOFA) score less than or equal to 1. SOFA total scores range from 0 to 24, with higher scores reflecting a worse clinical status or outcome. A SOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.</description>
          <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the frequency of Day 14 SOFA score less than or equal to 1 was not different among treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay (LOS)</title>
        <description>The duration of hospital stay over the 28-day study period.</description>
        <time_frame>28 days</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay (LOS)</title>
          <description>The duration of hospital stay over the 28-day study period.</description>
          <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="7.96"/>
                    <measurement group_id="O2" value="17.4" spread="9.07"/>
                    <measurement group_id="O3" value="20.0" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>Wilcoxon p value represents comparison of active dose groups versus placebo group.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit-free Days (ICU-free Days)</title>
        <description>The number of intensive care unit-free days (ICU-free days)</description>
        <time_frame>28 days</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit-free Days (ICU-free Days)</title>
          <description>The number of intensive care unit-free days (ICU-free days)</description>
          <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>ICU-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="8.48"/>
                    <measurement group_id="O2" value="21.3" spread="6.21"/>
                    <measurement group_id="O3" value="17.1" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>Wilcoxon p value represents comparison of active dose groups versus placebo group.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days</title>
        <description>The number of ventilator-free days (days without ventilator use)</description>
        <time_frame>28 days</time_frame>
        <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>AB103 0.25 mg/kg</title>
            <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O2">
            <title>AB103 0.5 mg/kg</title>
            <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days</title>
          <description>The number of ventilator-free days (days without ventilator use)</description>
          <population>Modified intent-to-treat (mITT) population: all randomized patients who received the proper study drug (AB103 or Placebo), had a definitive surgical diagnosis of NSTI, were not mis-dosed, and did not have a CD4 count &lt;200 cells/mm3. Proper study drug administration meant that study drug administration did not deviate from the planned administration. The number of patients analyzed is the number of patients with non-missing data in this population.</population>
          <units>ventilator-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="8.75"/>
                    <measurement group_id="O2" value="24.1" spread="6.25"/>
                    <measurement group_id="O3" value="20.8" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>Wilcoxon p value represents comparison of active dose groups versus placebo group.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) included in this summary were to be collected from dosing through Day 7; serious adverse events (SAEs) included in this summary were to be collected from dosing through Day 28.</time_frame>
      <desc>General, non-directed, systematic questioning of patients regarding AEs was to be performed at each study visit through Day 7. After Day 7, SAEs were to be assessed at each study visit through Day 28. Patients were able to voluntarily report AEs at any time.</desc>
      <group_list>
        <group group_id="E1">
          <title>AB103 0.25 mg/kg</title>
          <description>AB103 0.25 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="E2">
          <title>AB103 0.5 mg/kg</title>
          <description>AB103 0.5 mg/kg administered as a single IV infusion</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Normal saline (0.9% sodium chloride) administered as a single IV infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fungemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Operative hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Withdrawal of life support</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fungemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Operative hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haptoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>International normalized ratio abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Withdrawal of life support</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wayne M Dankner, MD, Chief Medical Officer</name_or_title>
      <organization>Atox Bio, Ltd.</organization>
      <phone>1 919-219-6377</phone>
      <email>wayned@atoxbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

